145 related articles for article (PubMed ID: 37548191)
1. Evaluation of prostate cancer tissue metabolomics: would clinics utilise it for diagnosis?
Bansal N; Kumar M; Sankhwar SN; Gupta A
Expert Rev Mol Med; 2023 Aug; 25():e26. PubMed ID: 37548191
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status.
Dudka I; Thysell E; Lundquist K; Antti H; Iglesias-Gato D; Flores-Morales A; Bergh A; Wikström P; Gröbner G
BMC Cancer; 2020 May; 20(1):437. PubMed ID: 32423389
[TBL] [Abstract][Full Text] [Related]
3. Relevance of emerging metabolomics-based biomarkers of prostate cancer: a systematic review.
Bansal N; Kumar M; Sankhwar SN; Gupta A
Expert Rev Mol Med; 2022 Jun; 24():e25. PubMed ID: 35730322
[TBL] [Abstract][Full Text] [Related]
4. Metabolomics Biomarkers of Prostate Cancer: A Systematic Review.
Kdadra M; Höckner S; Leung H; Kremer W; Schiffer E
Diagnostics (Basel); 2019 Feb; 9(1):. PubMed ID: 30791464
[TBL] [Abstract][Full Text] [Related]
5. Metabolomic Prediction of Human Prostate Cancer Aggressiveness: Magnetic Resonance Spectroscopy of Histologically Benign Tissue.
Vandergrift LA; Decelle EA; Kurth J; Wu S; Fuss TL; DeFeo EM; Halpern EF; Taupitz M; McDougal WS; Olumi AF; Wu CL; Cheng LL
Sci Rep; 2018 Mar; 8(1):4997. PubMed ID: 29581441
[TBL] [Abstract][Full Text] [Related]
6. Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence.
Kelly RS; Vander Heiden MG; Giovannucci E; Mucci LA
Cancer Epidemiol Biomarkers Prev; 2016 Jun; 25(6):887-906. PubMed ID: 27197278
[TBL] [Abstract][Full Text] [Related]
7. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
[TBL] [Abstract][Full Text] [Related]
8. NMR spectroscopy of filtered serum of prostate cancer: A new frontier in metabolomics.
Kumar D; Gupta A; Mandhani A; Sankhwar SN
Prostate; 2016 Sep; 76(12):1106-19. PubMed ID: 27197810
[TBL] [Abstract][Full Text] [Related]
9. Integration of Metabolomics and Transcriptomics Reveals Major Metabolic Pathways and Potential Biomarker Involved in Prostate Cancer.
Ren S; Shao Y; Zhao X; Hong CS; Wang F; Lu X; Li J; Ye G; Yan M; Zhuang Z; Xu C; Xu G; Sun Y
Mol Cell Proteomics; 2016 Jan; 15(1):154-63. PubMed ID: 26545398
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine.
Fredsøe J; Rasmussen AKI; Thomsen AR; Mouritzen P; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Eur Urol Focus; 2018 Dec; 4(6):825-833. PubMed ID: 28753866
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers in Prostate Cancer Diagnosis: From Current Knowledge to the Role of Metabolomics and Exosomes.
Salciccia S; Capriotti AL; Laganà A; Fais S; Logozzi M; De Berardinis E; Busetto GM; Di Pierro GB; Ricciuti GP; Del Giudice F; Sciarra A; Carroll PR; Cooperberg MR; Sciarra B; Maggi M
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922033
[TBL] [Abstract][Full Text] [Related]
12. New findings on urinary prostate cancer metabolome through combined GC-MS and
Lima AR; Pinto J; Barros-Silva D; Jerónimo C; Henrique R; Bastos ML; Carvalho M; Guedes Pinho P
Metabolomics; 2020 Jun; 16(6):70. PubMed ID: 32495062
[TBL] [Abstract][Full Text] [Related]
13. A novel non-canonical Wnt signature for prostate cancer aggressiveness.
Sandsmark E; Hansen AF; Selnæs KM; Bertilsson H; Bofin AM; Wright AJ; Viset T; Richardsen E; Drabløs F; Bathen TF; Tessem MB; Rye MB
Oncotarget; 2017 Feb; 8(6):9572-9586. PubMed ID: 28030815
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer diagnosis and characterization with mass spectrometry imaging.
Kurreck A; Vandergrift LA; Fuss TL; Habbel P; Agar NYR; Cheng LL
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):297-305. PubMed ID: 29209003
[TBL] [Abstract][Full Text] [Related]
15. NMR-Based Prostate Cancer Metabolomics.
Euceda LR; Andersen MK; Tessem MB; Moestue SA; Grinde MT; Bathen TF
Methods Mol Biol; 2018; 1786():237-257. PubMed ID: 29786797
[TBL] [Abstract][Full Text] [Related]
16. Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer.
Lucarelli G; Rutigliano M; Galleggiante V; Giglio A; Palazzo S; Ferro M; Simone C; Bettocchi C; Battaglia M; Ditonno P
Expert Rev Mol Diagn; 2015; 15(9):1211-24. PubMed ID: 26174441
[TBL] [Abstract][Full Text] [Related]
17.
Bruzzone C; Loizaga-Iriarte A; Sánchez-Mosquera P; Gil-Redondo R; Astobiza I; Diercks T; Cortazar AR; Ugalde-Olano A; Schäfer H; Blanco FJ; Unda M; Cannet C; Spraul M; Mato JM; Embade N; Carracedo A; Millet O
J Proteome Res; 2020 Jun; 19(6):2419-2428. PubMed ID: 32380831
[TBL] [Abstract][Full Text] [Related]
18. GC-MS-based metabolomics reveals new biomarkers to assist the differentiation of prostate cancer and benign prostatic hyperplasia.
Wang W; He Z; Kong Y; Liu Z; Gong L
Clin Chim Acta; 2021 Aug; 519():10-17. PubMed ID: 33831421
[TBL] [Abstract][Full Text] [Related]
19. Noninvasive urine metabolomics of prostate cancer and its therapeutic approaches: a current scenario and future perspective.
Kumar D; Nath K; Lal H; Gupta A
Expert Rev Proteomics; 2021 Nov; 18(11):995-1008. PubMed ID: 34821179
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]